Abstract: Provided herein are methods of determining a subject's metastatic potential, comprising measuring a level of expression of a gene, an RNA, or a protein, or a combination thereof, in a sample obtained from a synthetically-engineered pMN implanted in the subject, wherein the measured expression level of the gene, RNA, or protein in the sample is compared to a control level. Related methods are also provided herein.

Abstract: The present disclosure relates generally to techniques for capturing cancer cells and, more particularly, to techniques for capturing metastatic cancer cells in vivo.

Abstract: Pharmaceutical compositions and methods of inhibiting tumor cell proliferation of triple-negative (ER?/PR?/HER2?) breast cancer cells and for treating subjects with a form of breast cancer having a triple-negative (ER?/PR?/HER2?) phenotype are provided. The methods include a step of contacting triple-negative breast cancer cells with an effective amount of a composition including Eribulin and CYC065.